A procedure is described for determining the preferential killing of DNA repair-deficient E. coli. Dilute suspensions of DNA repair-proficient and -deficient bacteria are exposed to a graded series of test chemical concentrations. Survivors are determined by enumeration on agar plates. An expression used to express preferential killing (or lack thereof) is shown to be dose-dependent and potentially useful for determining genotoxic potencies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0165-1161(80)90236-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Tertiary amine modification enables triterpene nanoparticles to target the mitochondria and treat glioblastoma via pyroptosis induction.
Biomaterials
December 2024
Department of Neurosurgery, Yale University, New Haven, CT, 06511, USA; Department of Biomedical Engineering, Yale University, New Haven, CT, 06510, USA. Electronic address:
Glioblastoma (GBM), the most common primary brain tumor, lacks effective treatments. Emerging evidence suggests mitochondria as a promising therapeutic target, albeit successfully targeting represents a major challenge. Recently, we discovered a group of triterpenes that can self-assemble into nanoparticles (NPs) for cancer treatment.
View Article and Find Full Text PDFexhibits necrotrophic behavior when causing soft rot in ripe fruit.
Phytopathology
December 2024
University of California Davis Department of Plant Sciences, Davis, California, United States;
is known for causing soft rot in fruit and vegetables during postharvest. Although it has traditionally been considered a saprophyte, it appears to behave more like a necrotrophic pathogen. In this study, we propose that invades host tissues by actively killing host cells and overcoming the host defense mechanisms, as opposed to growing saprophytically on decaying plant matter.
View Article and Find Full Text PDFImpact of Gold Nanoparticles and Ionizing Radiation on Whole Chromatin Organization as Detected by Single-Molecule Localization Microscopy.
Int J Mol Sci
November 2024
Kirchhoff-Institute for Physics, Heidelberg University, Im Neuenheimer Feld 227, 69120 Heidelberg, Germany.
In radiation tumor therapy, irradiation, on one hand, should cause cell death to the tumor. On the other hand, the surrounding non-tumor tissue should be maintained unaffected. Therefore, methods of local dose enhancements are highly interesting.
View Article and Find Full Text PDFEntry into the lytic cycle exposes EBV-infected cells to NK cell killing via upregulation of the MICB ligand for NKG2D and activation of the CD56 and NKG2AKIRCD56 subsets.
Front Immunol
December 2024
Research Unit of Primary Immunodeficiency, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
The Epstein-Barr virus (EBV) is usually acquired during infancy as an asymptomatic infection and persists throughout life in a latent state under the control of the host immune system. However, EBV is associated with various malignant diseases that preferentially develop in immunodeficient individuals. Accumulating evidence suggests an important role for NK cells, though the mechanisms by which EBV evades or triggers NK cell responses are poorly understood.
View Article and Find Full Text PDFHigh-affinity T cell receptor ImmTAC® bispecific efficiently redirects T cells to kill tumor cells expressing the cancer-testis antigen PRAME.
Immunother Adv
November 2024
Immunocore Limited, Abingdon, Oxfordshire, United Kingdom.
Background: PRAME (eferentially expressed ntigen in lanoma) is a cancer-testis antigen expressed in several tumor indications, representing an attractive anticancer target. However, its intracellular location limits targeting by traditional methods. PRAME peptides are presented on the surface of tumor cells by human leukocyte antigen (HLA) molecules, indicating that a T cell receptor (TCR)-based strategy that redirects T cells to kill PRAME tumors could be a novel immunotherapeutic option.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!